(Q38008634)

26 August 2017

title

A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke (English)

1 reference

26 August 2017

main subject

cardiovascular disease

1 reference

Katherine M Carey

1

1 reference

26 August 2017

Morgan R Comee

series ordinal

2

1 reference

26 August 2017

Jennifer L Donovan

series ordinal

3

1 reference

26 August 2017

Abir O Kanaan

series ordinal

4

1 reference

26 August 2017

language of work or name

English

0 references

publication date

8 May 2012

1 reference

Annals of Pharmacotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

46

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

688-695

1 reference

A strategy to reduce cardiovascular disease by more than 80%

26 August 2017

cites work

1 reference

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial

21 January 2018

1 reference

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.

21 January 2018

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

21 January 2018

1 reference

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin

21 January 2018

1 reference

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

21 January 2018

1 reference

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial

21 January 2018

1 reference

The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

21 January 2018

1 reference

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

21 January 2018

1 reference

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk

21 January 2018

1 reference

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

21 January 2018

1 reference

Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis.

21 January 2018

1 reference

Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure

21 January 2018

1 reference

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

21 January 2018

1 reference

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

21 January 2018

1 reference

Homocysteine lowering with folic acid and B vitamins in vascular disease

21 January 2018

1 reference

Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

21 January 2018

1 reference

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers

21 January 2018

1 reference

Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension

21 January 2018

1 reference

A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.

21 January 2018

1 reference

A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization

21 January 2018

1 reference

An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk

21 January 2018

1 reference

Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1Q621

1 reference

26 August 2017

1 reference